Proposal for Combining ECOG Myeloma Trial SNP Data
OBJECTIVES:
- Determine whether there is an increased frequency of 1 or more polymorphic alleles that
are associated with clinical endpoints using custom myeloma single nucleotide
polymorphism (SNP) chip analysis of banked DNA samples from patients with multiple
myeloma.
- Determine SNPs associated with toxicities caused, not by variations in tumor cell
genetics, but by individual genetic variations affecting drug activation, distribution,
metabolism, and export (ADME).
- Determine SNPs associated with response, influenced by the same ADME.
- Determine SNPs associated with bone disease (as a variable) among patients with
multiple myeloma.
- Determine SNPs associated with epidemiology (i.e., risk factors for the development of
multiple myeloma).
OUTLINE: This is a retrospective, multicenter study.
Banked DNA samples are analyzed using a custom single nucleotide polymorphism (SNP) chip to
assess approximately 3,590 SNPs from 1,061 genes that are associated with myeloma growth and
response.
PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.
Observational
N/A
Increased frequency of ≥1 polymorphic alleles associated with clinical endpoints using custom myeloma SNP chip analysis of banked DNA samples from patients with multiple myeloma
No
Brian Van Ness
Study Chair
Masonic Cancer Center, University of Minnesota
Unspecified
CDR0000495284
NCT00898040
Name | Location |
---|